In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Inc.

www.biogen.com

Latest From Biogen Inc.

Biogen Taken To Task Over Spinraza Price In Belgium & Italy

Excessive pricing is once again under the spotlight In Europe. Consumer rights organizations in Belgium and Italy have referred Biogen to the national competition authorities over “exorbitant pricing.”

Europe Belgium

UK's AstronauTx Gets Cash For Alzheimer's Programs

The Dementia Discovery Fund is backing the UCL spin-off's efforts to develop therapies that modulate astrocyte function.

Financing Neurology

E2082 Discontinuation May Hit Eisai's Epilepsy Succession

Fatality of healthy volunteer in early clinical trial prompts halt of all clinical work for candidate anti-epileptic, potentially hitting Eisai's product succession strategy in a core therapeutic area.

Japan Clinical Trials

Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate

Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.

Deals M & A
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register